SEC filings and other documents

Positive clinical data, higher licensing revenue, and new equity funding offset by net loss and funding risks.

Shareholders approved all proposals as clinical and financial milestones were highlighted.

Returned to profitability in Q1 2026 on licensing revenue, but faces funding and listing risks.

Advancing fusion immunotherapeutics for autoimmune diseases and cancer, with key clinical milestones ahead.

FY 2025 net loss narrowed, but going concern and Nasdaq compliance risks persist.

Revenue fell sharply and net loss persisted, with urgent funding and Nasdaq compliance needs.

Net loss narrowed and debt was reduced, but revenue fell and funding risks remain.

Net loss narrowed in Q1 2025 amid lower revenue and ongoing funding challenges.

Raised funds, advanced clinical programs, and ratified key governance proposals at the AGM.

Lower revenue, higher net loss, and urgent need for funding amid pipeline progress.

Expanded pipeline and legal resolution, but urgent financing needed amid going concern risk.

Q2 2024 net loss widened to $15.3M amid surging legal costs and ongoing liquidity concerns.